Phase II, open-label study of encorafenib plus binimetinib in patients with BRAFV600-mutant metastatic non-small-cell lung cancer

Authors

Gregory J Riely, Memorial Sloan Kettering Cancer Center
Daniel Morgensztern, Washington University School of Medicine in St. Louis
et al.

Journal

Journal of Clinical Oncology

Publication Date

7-20-2023

Volume

41

Issue

21

First Page

3700

Last Page

3711

Document Type

Open Access Publication

DOI

10.1200/JCO.23.00774

Acceptable Secondary Publication – Plain Language Summary

https://doi.org/10.2217/fon-2023-0859

Rights and Permissions

Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussain M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BE. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 Jul 20;41(21):3700-3711. doi: 10.1200/JCO.23.00774. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Recommended Citation

Riely, Gregory J; Morgensztern, Daniel; and et al., "Phase II, open-label study of encorafenib plus binimetinib in patients with BRAFV600-mutant metastatic non-small-cell lung cancer." Journal of Clinical Oncology. 41, 21. 3700 - 3711. (2023).
https://digitalcommons.wustl.edu/oa_4/2178

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.